162 related articles for article (PubMed ID: 9034981)
1. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
[TBL] [Abstract][Full Text] [Related]
2. The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis.
Kamper EF; Kopeikina LT; Trontzas P; Potamianou A; Tsiroglou E; Stavridis JC
J Rheumatol; 2000 Nov; 27(11):2545-50. PubMed ID: 11093432
[TBL] [Abstract][Full Text] [Related]
3. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
4. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
7. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
8. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Raaphorst J; Johan Groeneveld AB; Bossink AW; Erik Hack C
Thromb Haemost; 2001 Aug; 86(2):543-9. PubMed ID: 11522001
[TBL] [Abstract][Full Text] [Related]
9. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
[TBL] [Abstract][Full Text] [Related]
10. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
12. Elastase- and plasmin-mediated fibrinolysis in rheumatoid arthritis.
Carmassi F; De Negri F; Morale M; Puccetti R; Chung SI
Int J Tissue React; 1994; 16(2):89-93. PubMed ID: 7960505
[TBL] [Abstract][Full Text] [Related]
13. An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion.
Speidl WS; Zeiner A; Nikfardjam M; Geppert A; Jordanova N; Niessner A; Zorn G; Maurer G; Schreiber W; Wojta J; Huber K
J Am Coll Cardiol; 2005 Jan; 45(1):30-4. PubMed ID: 15629369
[TBL] [Abstract][Full Text] [Related]
14. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
15. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
17. Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders.
Jurado M; Páramo JA; Gutierrez-Pimentel M; Rocha E
Thromb Haemost; 1992 Nov; 68(5):516-20. PubMed ID: 1455397
[TBL] [Abstract][Full Text] [Related]
18. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of t-PA, PAI-2, IL-1beta and PGE(2) in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease.
Biyikoğlu B; Buduneli N; Kardeşler L; Aksu K; Oder G; Kütükçüler N
J Clin Periodontol; 2006 Sep; 33(9):605-11. PubMed ID: 16856901
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity in multiple myeloma.
Yağci M; Sucak GT; Haznedar R
Am J Hematol; 2003 Dec; 74(4):231-7. PubMed ID: 14635202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]